Sunitinib malate for the treatment of solid tumours: a review of current clinical data

被引：96

作者：

Motzer, Robert J.

Hoosen, Sakina

Bello, Carlo L.

Christensen, James G.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Pfizer Inc, New York, NY 10017 USA

[3] Pfizer Global Res & Dev, San Diego, CA 92121 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2006年 / 15卷 / 05期

关键词：

antiangiogenic; antitumour; GIST; multitargeted tyrosine kinase inhibitor; RCC; solid tumours; SU11248; sunitinib;

D O I：

10.1517/13543784.15.5.553

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Receptor tyrosine kinases (RTKs) play important roles in the regulation of cellular growth, and mutated or overexpressed RTKs have been implicated in various human cancers. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor with antitumour and antiangiogenic activity that recently received approval from the FDA for the treatment of advanced renal cell carcinoma and of gastrointestinal stromal tumours after disease progression on or intolerance to imatinib mesilate therapy. Sunitinib has also demonstrated promising clinical activity in the treatment of other advanced solid tumours. The present review provides an updated summary of emerging clinical experience with this promising new anticancer agent.

引用

页码：553 / 561

页数：9

共 55 条

[1]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[2] Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects [J].